Who
Sushil Patel
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Replimune Group; Director, Revolution Medicines.
In numbers
- Trades disclosed
- 72
- Buys
- 0
- Sells
- 13
- Bought
- $0
- Sold
- $5.1M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 3 May 2021
- Last trade
- 10 Aug 2026
- Last filed
- 12 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Aug 2026filed 12 Aug 2026 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $510K39,341 at $12.97 | filing |
| 10 Aug 2026filed 12 Aug 2026 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $510K39,341 at $12.97 | filing |
| 29 Jun 2026filed 1 Jul 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Code M | $111K2,955 at $37.54 | filing |
| 29 Jun 2026filed 1 Jul 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $170K881 at $192.61 | filing |
| 29 Jun 2026filed 1 Jul 2026 | RVMD Revolution Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,955 at $0.00 | filing |
| 29 Jun 2026filed 1 Jul 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $55K300 at $183.17 | filing |
| 29 Jun 2026filed 1 Jul 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $166K900 at $184.59 | filing |
| 29 Jun 2026filed 1 Jul 2026 | RVMD Revolution Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,955 at $0.00 | filing |
| 29 Jun 2026filed 1 Jul 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $204K1,100 at $185.90 | filing |
| 29 Jun 2026filed 1 Jul 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $160K858 at $186.92 | filing |
| 29 Jun 2026filed 1 Jul 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $56K300 at $187.83 | filing |
| 29 Jun 2026filed 1 Jul 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $19K100 at $188.57 | filing |
| 29 Jun 2026filed 1 Jul 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $114K600 at $190.55 | filing |
| 29 Jun 2026filed 1 Jul 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $104K541 at $191.87 | filing |
| 29 Jun 2026filed 1 Jul 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Code M | $111K2,955 at $37.54 | filing |
| 29 Jun 2026filed 1 Jul 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $55K300 at $183.17 | filing |
| 29 Jun 2026filed 1 Jul 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $166K900 at $184.59 | filing |
| 29 Jun 2026filed 1 Jul 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $204K1,100 at $185.90 | filing |
| 29 Jun 2026filed 1 Jul 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $160K858 at $186.92 | filing |
| 29 Jun 2026filed 1 Jul 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $56K300 at $187.83 | filing |
News
Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026RVMD · manilatimes.net · 23 Oct 2026Contrasting Revolution Medicines (NASDAQ:RVMD) and Agios Pharmaceuticals (NASDAQ:AGIO)RVMD · themarketsdaily.com · 22 Oct 20263,946 Shares of Revolution Medicines, Inc. $RVMD Acquired by Vontobel Holding Ltd.RVMD · dailypolitical.com · 21 Oct 2026
0 headlines in the last 90 days name Sushil Patel; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.